Amylyx Pharmaceuticals’ (AMLX) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of Amylyx Pharmaceuticals (NASDAQ:AMLX) in a research note released on Friday, MarketBeat reports. The brokerage currently has a $8.00 target price on the stock.

Separately, The Goldman Sachs Group boosted their price objective on shares of Amylyx Pharmaceuticals from $3.00 to $4.00 and gave the stock a “neutral” rating in a report on Friday, July 12th. Six investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, Amylyx Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $15.33.

Amylyx Pharmaceuticals Price Performance

Shares of AMLX stock opened at $4.78 on Friday. Amylyx Pharmaceuticals has a 12 month low of $1.58 and a 12 month high of $19.95. The firm has a market capitalization of $325.07 million, a P/E ratio of -4.47 and a beta of -0.55. The company’s fifty day moving average price is $2.77 and its two-hundred day moving average price is $2.22.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.73) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.35). Amylyx Pharmaceuticals had a negative return on equity of 15.51% and a negative net margin of 17.86%. The firm had revenue of ($1.02) million during the quarter, compared to analyst estimates of $18.83 million. During the same quarter in the prior year, the firm earned $0.31 EPS. On average, sell-side analysts anticipate that Amylyx Pharmaceuticals will post -2.27 EPS for the current year.

Insider Activity

In other Amylyx Pharmaceuticals news, Director George M. Milne, Jr. acquired 100,000 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The stock was acquired at an average price of $2.20 per share, with a total value of $220,000.00. Following the transaction, the director now directly owns 858,571 shares in the company, valued at approximately $1,888,856.20. This represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In related news, Director George M. Milne, Jr. acquired 100,000 shares of Amylyx Pharmaceuticals stock in a transaction that occurred on Tuesday, September 3rd. The stock was acquired at an average price of $2.20 per share, for a total transaction of $220,000.00. Following the transaction, the director now directly owns 858,571 shares of the company’s stock, valued at $1,888,856.20. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Justin B. Klee sold 18,589 shares of the company’s stock in a transaction on Monday, September 30th. The stock was sold at an average price of $3.20, for a total value of $59,484.80. Following the transaction, the chief executive officer now owns 3,120,569 shares of the company’s stock, valued at approximately $9,985,820.80. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 11.70% of the company’s stock.

Institutional Trading of Amylyx Pharmaceuticals

A number of large investors have recently modified their holdings of the company. Goldman Sachs Group Inc. grew its position in Amylyx Pharmaceuticals by 5.9% in the 4th quarter. Goldman Sachs Group Inc. now owns 1,256,861 shares of the company’s stock worth $18,501,000 after purchasing an additional 69,733 shares during the last quarter. Hennion & Walsh Asset Management Inc. increased its position in Amylyx Pharmaceuticals by 32.9% in the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 112,867 shares of the company’s stock valued at $321,000 after acquiring an additional 27,937 shares during the period. Allspring Global Investments Holdings LLC raised its stake in Amylyx Pharmaceuticals by 52,575.9% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 15,276 shares of the company’s stock valued at $43,000 after acquiring an additional 15,247 shares in the last quarter. Capstone Investment Advisors LLC boosted its position in Amylyx Pharmaceuticals by 300.4% during the 1st quarter. Capstone Investment Advisors LLC now owns 80,084 shares of the company’s stock worth $227,000 after acquiring an additional 60,084 shares during the period. Finally, Swiss National Bank grew its stake in shares of Amylyx Pharmaceuticals by 8.7% in the first quarter. Swiss National Bank now owns 86,600 shares of the company’s stock worth $246,000 after purchasing an additional 6,900 shares in the last quarter. Institutional investors and hedge funds own 95.84% of the company’s stock.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.